Humans Immunotherapy Inflammation Prognosis Progression-Free Survival *Urinary Bladder Neoplasms

Bcg Bacillus Calmette–Guérin Nmibc bladder cancer checkpoint inhibition therapy nadofaragene firadenovec non muscle invasive oncolytic viruses

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

Humans Female Male Infant *Urinary Bladder Neoplasms/diagnosis/therapy/pathology *Carcinoma Transitional Cell/pathology Urinary Bladder/pathology Neoplasm Staging Cystoscopy Cystectomy/methods

Bladder cancer neoadjuvant chemotherapy radical cystectomy systematic review variant histology urothelial cancer

Adjuvants Immunologic Administration Intravesical BCG Vaccine/therapeutic use Bayes Theorem *Covid-19 Duration of Therapy Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy Network Meta-Analysis Pandemics *Urinary Bladder Neoplasms/drug therapy *Urology

*Carcinoma Renal Cell/complications/epidemiology *Carcinoma Transitional Cell/complications/epidemiology Cross-Sectional Studies Hematuria/epidemiology/etiology Humans Incidence *Kidney Neoplasms/complications/epidemiology Male Prospective Studies Retrospective Studies Risk Factors *Urinary Bladder Neoplasms/complications/epidemiology Age distribution Cystoscopy Haematuria Kidney neoplasms Radiotherapy Sex Smoking Transitional cell carcinoma Urinary bladder neoplasms Urological neoplasms

*Antineoplastic Agents/adverse effects *Carcinoma Transitional Cell/drug therapy Humans Mutation Receptor ErbB-2 Trastuzumab/adverse effects *Urinary Bladder Neoplasms/drug therapy Erbb2 Her2 Metastatic bladder cancer Metastatic urothelial cancer Targeted treatment

Humans *Carcinoma Transitional Cell/radiotherapy/surgery/drug therapy *Urinary Bladder Neoplasms Radiotherapy Adjuvant Retrospective Studies Prospective Studies Neoplasm Recurrence Local adjuvant radiotherapy external beam genitourinary locoregional control meta-analysis proximal ureter renal pelvis survival systematic review upper tract urothelial carcinoma

*Carcinoma Transitional Cell/drug therapy Female Humans Immune Checkpoint Inhibitors/therapeutic use Immunotherapy *Lung Neoplasms/pathology Male Platinum/therapeutic use Programmed Cell Death 1 Receptor *Urinary Bladder Neoplasms/drug therapy

*Cystectomy Humans *Neoadjuvant Therapy Neoplasm Staging Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery

Administration Intravesical *Carcinoma Transitional Cell/pathology Epirubicin/therapeutic use Female Humans Male Mitomycin/therapeutic use Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/pathology Intravesical Chemotherapy Non-muscle Invasive Bladder Cancer Turb

adjuvant chemotherapy bladder cancer cystectomy

Administration Intravesical *Carcinoma Transitional Cell/pathology Humans Male Neoplasm Invasiveness/pathology Neoplasm Recurrence Local/pathology Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/therapy

Humans *Carcinoma Transitional Cell/diagnosis/therapy *Urinary Bladder Neoplasms Systematic Reviews as Topic Kidney Oregon *Ureteral Neoplasms/diagnosis/therapy Utuc renal pelvis cancer upper tract urothelial cancer ureteral cancer urothelial cancer

Humans Administration Intravesical Antibiotics Antineoplastic/administration & dosage Hematuria/drug therapy *Mitomycin/administration & dosage Prospective Studies Quality of Life Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology/surgery

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

*Carcinoma Transitional Cell/drug therapy/pathology Cisplatin Female Humans Male *Urinary Bladder Neoplasms/drug therapy/pathology *Urology *Bladder cancer *European Association of Urology *Guidelines *Immunotherapy *Metastatic *Systemic therapy *Urothelial carcinoma

*Carcinoma Transitional Cell/pathology/surgery Combined Modality Therapy Consensus Humans Neoplasm Invasiveness/pathology Quality of Life Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/drug therapy/surgery Bladder neoplasms Bladder preservation Expert consensus Multi-disciplinary treatment

Cystectomy France Humans Lymphatic Irradiation Palliative Care Patient Positioning Radiation Oncology Radiotherapy Dosage Radiotherapy Adjuvant Radiotherapy Conformal Urinary Bladder Neoplasms/diagnostic imaging/pathology/*radiotherapy/surgery Bladder cancer Cancers de la vessie Chemoradiation Chimioradiothérapie French society for radiation oncology Guidelines Radiation therapy Radiothérapie Recommandations Société française de radiothérapie oncologique